Elsevier

Early Human Development

Volume 1, Issue 2, October 1977, Pages 159-169
Early Human Development

The narcotic-dependent mother: Fetal and neonatal consequences

https://doi.org/10.1016/0378-3782(77)90017-2Get rights and content

Abstract

During the years 1971–1974, 230 infants born to drug-dependent women and 33 infants born to ex-addicts were studied. Heroin abuse declined while methadone usage increased during those years. Compared to heroin abuse, methadone maintenance treatment during pregnancy was associated with more consistent prenatal care, more normal fetal growth and reduced fetal mortality. Meconium staining of amniotic fluid was increased in the heroin and heroin-methadone groups; this was not associated, however, with an increase in meconium aspiration or a reduction in Apgar scores. Of special note was the equally severe intrauterine growth retardation of infants of former heroin addicts who were free of narcotic use during pregnancy.

Neonatal withdrawal from methadone appeared to be more severe than from heroin, as judged by amount of medication required to control symptoms and duration of treatment. In all groups, central nervous system signs were the most common manifestations of withdrawal. Severity of withdrawal did not correlate with late pregnancy maternal methadone dosage. Neonatal seizures occurred in 1.5% of the heroin group and 10% of the methadone group.

Discharge of an infant to a parent rather than to an alternate care-taker was more likely if the mother was enrolled in a methadone treatment program. Methadone maintenance programs appear to offer significant therapeutic benefits, balancing the untoward effects of the drug on the newborn infant.

References (30)

  • R.W. Cobrinik et al.

    The effect of maternal narcotic addiction on the newborn infant; review of literature and report of 22 cases

    Pediatrics

    (1959)
  • C. Zelson et al.

    Neonatal narcotic addiction: 10 year observation

    Pediatrics

    (1971)
  • A.M. Reddy et al.

    Observations on heroin and methadone withdrawal in the newborn

    Pediatrics

    (1971)
  • P.J. Lipsitz et al.

    Newborn infants of mothers on mothadone maintenance

    N.Y. State J. Med.

    (1974)
  • R.G. Harper et al.

    The effect of a methadone treatment program upon pregnant heroin addicts and their newborn infants

    Pediatrics

    (1974)
  • Cited by (147)

    • No. 349-Substance Use in Pregnancy

      2017, Journal of Obstetrics and Gynaecology Canada
    • N<sup>o</sup> 349 – Consommation de substances psychoactives pendant la grossesse

      2017, Journal of Obstetrics and Gynaecology Canada
      Citation Excerpt :

      La méthadone est un agoniste pur dont l'effet augmente avec la dose. Les avantages de son administration pendant la grossesse sont nombreux : amélioration des soins prénataux75,92–94, gestation prolongée29,95, augmentation du poids à la naissance96,97, hausse de la proportion d'enfants confiés aux soins de leur mère28,75,86,93,98–105, etc. Même si les nouveau-nés dont la mère recevait de la méthadone ont tendance à être plus petits (poids à la naissance, taille, circonférence de la tête) que ceux non exposés à des drogues, des études ont montré que l'écart de croissance était comblé à l'âge de 12 mois105,106.

    • Infants Born to Opioid-Dependent Women in Ontario, 2002–2014

      2017, Journal of Obstetrics and Gynaecology Canada
      Citation Excerpt :

      Compared with the outcomes in unexposed infants, prenatal opioid exposure is associated with adverse perinatal outcomes and increased health care costs.3 Placental transmission of illicit opioids and opioid agonist therapies such as methadone and buprenorphine leads to fetal dependence and neonatal withdrawal (neonatal abstinence syndrome).4 NAS affects neonatal adaptation in critical areas of sleep, feeding, and autonomic function.5,6

    View all citing articles on Scopus

    Currently Chief, Division of Neonatology, Beth Israel Medical Center, 10 Nathan D. Perlman Place, New York, N.Y. 10003, U.S.A.

    View full text